SPPI Investors Have Opportunity to Lead Spectrum Pharmaceuticals, Inc. Securities Fraud Lawsuit

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Spectrum Pharmaceuticals common stock during the specified Class Period, indicating potential legal issues for the company related to misleading statements about its clinical trial [1][5]. Group 1: Lawsuit Details - The class action lawsuit is filed for investors who purchased Spectrum Pharmaceuticals common stock between May 12, 2022, and September 22, 2022 [1]. - The lawsuit claims that Spectrum made false or misleading statements regarding its PINNACLE Study, which involved the drug poziotinib intended for lung cancer treatment [5]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Next Steps for Investors - Investors wishing to join the class action can do so by visiting the provided link or contacting the law firm directly [3][5]. - The lead plaintiff process has been reopened, and interested parties must move the Court by September 24, 2025, to serve as lead plaintiff [1][3]. Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has consistently ranked highly in securities class action settlements and has recovered hundreds of millions of dollars for investors [4].